The COSMIC-313 trial tested two different triplet therapy regimens in patients with advanced renal cell carcinoma. Choueiri et al presented results from the study during a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2022 (Abstract LBA8).
